Umberto Basso

Padova, 35128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 188 publications

Real-World Outcomes of DNA Damage Repair Altered Metastatic Castration-Resistant Prostate Cancer: Insights from FFPE-Based Genomic Profiling.

Real-World Outcomes of DNA Damage Repair Altered Metastatic Castration-Resistant Prostate Cancer: Insights from FFPE-Based Genomic Profiling.

Journal: Cancers

Published: June 10, 2026

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Journal: Minerva urology and nephrology

Published: April 23, 2026

Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.

Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.

Journal: Scientific reports

Published: April 06, 2026

Choriocarcinoma: Diagnosis, treatment and management of a rare germ cell tumour. An update review.

Choriocarcinoma: Diagnosis, treatment and management of a rare germ cell tumour. An update review.

Journal: Tumori

Published: February 24, 2026

Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.

Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.

Journal: NPJ precision oncology

Published: January 18, 2026

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Journal: Prostate cancer and prostatic diseases

Published: January 03, 2026

Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors study.

Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors study.

Journal: British journal of cancer

Published: November 01, 2025

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Journal: Cancers

Published: October 26, 2025

Juxtapapillary retinal hemangioblastoma remission in a von Hippel-Lindau patient treated with cabozantinib.

Juxtapapillary retinal hemangioblastoma remission in a von Hippel-Lindau patient treated with cabozantinib.

Journal: American journal of ophthalmology case reports

Published: October 23, 2025

A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study.

A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study.

Journal: In vivo (Athens, Greece)

Published: August 09, 2025

Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.

Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.

Journal: The oncologist

Published: July 30, 2025

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.

Journal: Cancer immunology, immunotherapy : CII

Published: July 05, 2025

Showing 1-12 of 188

Last Updated: 09/26/2026